The significant discount of the trailing P/E to the forward multiple indicates that current earnings are not representative of the company's expected trajectory, a common pattern for firms in a rapid commercial ramp. The P/S ratio of 2.09 is modest for a high-growth biotech, but the P/B of 1.64 is elevated relative to tangible book value, reflecting the market's valuation of the commercial opportunity and intellectual property. Investors should monitor whether the implied growth rate embedded in the forward multiples is achievable as the initial launch surge normalizes.

The decline in gross margin is a critical trend to monitor, as it directly impacts the company's ability to sustain its strong operating margin of 42.1%. The operating margin itself remains robust, indicating effective control over SG&A and R&D expenses relative to revenue growth. However, the net margin of 25.5% is significantly lower than the operating margin, which may indicate the impact of non-operating items or taxes, warranting a closer look at the quality of earnings.

The sharp decline in ROIC is a mathematical consequence of the massive increase in invested capital from the equity and debt raises, which have not yet been fully deployed into earnings-generating assets. The ROE of 5.8% is similarly depressed by the enlarged equity base. This pattern is typical for companies that have just completed a major capital raise to fund a commercial launch; the key question is whether the new capital will generate returns that exceed the company's cost of capital over the medium term.

The lengthening CCC is a red flag for a company in a rapid growth phase, as it ties up cash that could otherwise be used for operations or growth. The DSO of 141 days is particularly concerning and may indicate that CorMedix is extending generous payment terms to secure large orders, which could pose a risk to cash flow if collections slow. The DPO of 42 days is relatively short, suggesting the company has limited leverage with its suppliers, further straining working capital.

The addition of debt is a significant shift in capital structure for a company that was previously equity-financed. While the D/E ratio of 0.31 is not high in absolute terms, the interest coverage ratio is not available for recent quarters, making it difficult to assess the comfort of debt service. The D/EBITDA of 2.73 suggests the debt load is manageable relative to current earnings, but this metric is highly sensitive to the sustainability of EBITDA as margins normalize.